San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Trefoil Therapeutics is raising $28,010,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, David Eveleth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Trefoil Therapeutics

Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.

To learn more about Trefoil Therapeutics, visit http://www.trefoiltherapeutics.com/

Contact:
David Eveleth, Chief Executive Officer
917-628-8502
develeth@trefoiltherapeutics.com
https://www.linkedin.com/in/david-eveleth-6407ba1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved